Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia.

Takeshi OsonoiShinichiro ShirabeMiyoko SaitoMitsuru HosoyaNorie WatahikiSatako DouguchiKensuke OfuchiMakoto Katoh

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2023)

These findings suggest that a 12-week course of dapagliflozin causes an increase in hemoglobin levels due to its hematopoietic effects in elderly type 2 diabetics with renal impairment, but that these effects may be independent of body water loss and iron metabolism improvement.

Keyphrases

iron deficiency
bone marrow
type diabetes
clinical trial
community dwelling